新型免疫调节药pomalidomide  

Pomalidomide: a new immunomudulatory drug

作　　者：郭跃龙[1] 伏世建[1] 程呈[1] 王宇[1] 

机构地区：[1]江苏奥赛康药业股份有限公司,南京210000

出　　处：《中国新药杂志》2013年第20期2349-2352,2378,共5页Chinese Journal of New Drugs

摘　　要：目前越来越多的骨髓瘤患者对硼替佐米或来那度胺的治疗耐药或有明显不良反应。pomalidomide是一种新型免疫调节剂,具有高效免疫调节作用,对复发性,难治性骨髓瘤具有显著作用。临床研究显示其耐受性较好,且给药方便,与沙利度胺和来那度胺相比,用量较小,疗效更佳。pomalidomide于2013年2月被美国FDA批准用于治疗先前已经接受过包括来那度胺和硼替佐米治疗的但又出现疾病进展的多发性骨髓瘤患者。本文对其药理作用、药动学、临床研究和不良反应等进行综述。There are an increasing number of patients who are refractory or experience significant adverse reaction to either bortezomib or lenalidomide therapy. Pomalidomide is a new immunomudulatory drug, which has significant activity in relapsed, refractory myeloma with potent immunomodulatory effect. Pomalidomide is well tolerated in clinical study and it can be convenient administrated. Compared with thalidomide and lenalidomide, pomalidomide has better efficacy with lower doses. Pomalidomide was approved by FDA for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression. In this article, the pharmacology, pharmacokinetics, clinical efficacy and adverse reaction of pomalidomide were reviewed.

关 键 词：POMALIDOMIDE 免疫调节剂 难治性 多发性骨髓瘤 

分 类 号：R979.1[医药卫生—药品]